# Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations

> **NCT06630221** · PHASE2 · RECRUITING · sponsor: **Abhay Singh, MD MPH** · enrollment: 25 (estimated)

## Conditions studied

- Myelodysplastic Syndromes
- Chronic Myelomonocytic Leukemia

## Interventions

- **DRUG:** Eltrombopag (EPAG)

## Key facts

- **NCT ID:** NCT06630221
- **Lead sponsor:** Abhay Singh, MD MPH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-17
- **Primary completion:** 2028-01-01
- **Final completion:** 2030-01-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06630221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06630221, "Eltrombopag as a Novel Therapeutic Approach for Low-risk MDS and CMML With TET2 Mutations". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT06630221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*